FDA Draft Guidance Outlines Statistical Considerations for Proving Biosimilarity

Drug Industry Daily
A A
Biosimilar sponsors should take a risk-based approach when assessing similarity of a reference product’s quality attributes, the FDA said in new draft guidance — pitched as part of the agency’s effort to lower drug prices.

To View This Article:

Login

Subscribe To Drug Industry Daily